WEBULL
News
KRYS
234.13
+5.48%
12.17
Krystal Biotech President Suma Krishnan Reports Disposal of Common Shares
Reuters · 15h ago
Krish S. Krishnan, President and CEO, Reports Disposal of Krystal Biotech Inc. Common Shares
Reuters · 15h ago
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?
NASDAQ · 22h ago
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Benzinga · 1d ago
US High Growth Tech Stocks To Watch
Simply Wall St · 5d ago
Weekly Report: what happened at KRYS last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at KRYS last week (1117-1121)?
Weekly Report · 11/24 10:24
How Investors Are Reacting To Krystal Biotech (KRYS) Surging Revenue and Global VYJUVEK Expansion
Simply Wall St · 11/21 20:17
Krystal Biotech (KRYS): Assessing Valuation Following Strong Q3 Results and Global Expansion Moves
Simply Wall St · 11/20 15:27
Krystal Biotech treatment of Hailey-Hailey disease granted orphan status
TipRanks · 11/20 15:00
Weekly Report: what happened at KRYS last week (1110-1114)?
Weekly Report · 11/17 10:24
Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth
Seeking Alpha · 11/16 14:00
How Investors May Respond To Krystal Biotech (KRYS) Surging Net Income and EPS Growth in Q3 2025
Simply Wall St · 11/14 17:35
Insiders Favor These 3 Growth Companies With Strong Ownership
Simply Wall St · 11/13 11:06
Krystal Biotech (KRYS): Assessing Valuation Following Strong Earnings Surge and Investor Optimism
Simply Wall St · 11/12 18:29
Weekly Report: what happened at KRYS last week (1103-1107)?
Weekly Report · 11/10 10:21
Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings
Simply Wall St · 11/10 10:04
What's Driving the Market Sentiment Around Krystal Biotech Inc?
Benzinga · 11/06 18:00
Why Krystal Biotech (KRYS) Is Up 8.0% After Surging VYJUVEK Revenue and Global Expansion
Simply Wall St · 11/06 15:45
A Look at Krystal Biotech's Valuation Following Strong Earnings Growth and Investor Interest
Simply Wall St · 11/05 14:35
More
Webull provides a variety of real-time KRYS stock news. You can receive the latest news about Krystal Biotech through multiple platforms. This information may help you make smarter investment decisions.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.